SABCS 2024: breaking news
As SABCS (10–14th December 2024, TX, USA) unfolds we’re bringing you the most significant headlines from the conference in one convenient place. Stay tuned to this space for continuous updates on the latest breaking news.
This year’s symposium features several talks poised to transform clinical practice. Discover which key presentations and themes to watch out for in our exclusive conference report by Consultant Breast Surgeon John Benson (Cambridge University Hospitals NHS Foundation Trust, UK).
Latest news
ESR1 breast cancer: could a brain-penetrating SERD pill advance treatment?
Data from the EMBER-3 trial has highlighted the potential of a next-generation selective estrogen receptor degrader (SERD) termed imlunestrant for certain ER-positive, HER2-negative advanced breast cancer. The promising results of the trial could provide an oral therapy option for many patients whose recurrent breast cancers harbor ESR1 mutations.
ZEST trial challenges provide insights into the use of ctDNA in predicting breast cancer recurrence
The ZEST trial, the first Phase III study of MRD-guided therapy in breast cancer, offered valuable insights into the potential of ctDNA as a predictor of breast cancer recurrence, despite its early termination.
OlympiA continues to demonstrate significant survival benefits of olaparib for high-risk BRCA+ patients
Findings from the third interim analysis of the Phase III OlympiA trial have strengthened olaparib’s role in reducing recurrence and improving overall survival in high-risk BRCA-positive breast cancer patients. The trial also highlighted olaparib’s efficacy across subgroups, including triple-negative and estrogen receptor-positive breast cancers, as well as the potential for its expanded use in lower-risk BRCA-positive cancers.
Should tamoxifen be considered for DCIS patients after breast conserving surgery?
The combined dataset of two clinical trials shows tamoxifen significantly decreases ipsilateral breast recurrence in “good risk” ductal carcinoma in situ patients who forgo radiation. Knowing the impact of tamoxifen on recurrence risk could help patients to make informed decisions about adjuvant treatments and allow them to effectively weigh the risks and benefits of different treatment options.